Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, INMUNE BIO INC. reported revenue of $0M, up 257.1% year over year. Operating margin was -94766.0% and net margin -91866.0%, on a free-cash-flow margin of -47248.0% with capital expenditure at 2084.0% of revenue. Every figure is computed directly from INMB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -94766.0% | -91866.0% |
| FY2024 | $0M | -304535.7% | -300585.7% |
| FY2023 | $0M | -19187.7% | -19360.0% |
| FY2022 | $0M | -6938.8% | -7299.2% |
| FY2021 | $0M | -16106.6% | -16762.4% |
How does INMB compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.